Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$2.67 USD
-0.01 (-0.37%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.68 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Orchestra BioMed Holdings, Inc.'s return on equity, or ROE, is -189.26% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that OBIO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
OBIO 2.67 -0.01(-0.37%)
Will OBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OBIO
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Other News for OBIO
Orchestra BioMed secures over $111M in proceeds, committed capital
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following ...
12 Health Care Stocks Moving In Friday's Intraday Session
Orchestra BioMed (OBIO) Sets Public Offering at $2.75 Per Share
Orchestra BioMed announces pricing of $40 million public offering